SEATTLE, April 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a presentation discussing its Hybrid mRNA TechnologyTM as well as its lead product candidate, PRX-OTC, at the TIDES Oligonucleotide and Peptide Technology and Product Development Conference, to be held at the Manchester Grand Hyatt, April 30-May 3, 2017 in San Diego. PRX-OTC is in development for the treatment of ornithine transcarbamylase deficiency.
Title of Presentation: Targeted mRNA Delivery to the Liver for Intracellular Enzyme Replacement Therapy (i-ERT)
Presenter: Michael Houston, Ph.D., Chief Scientific Officer
Time: Tuesday, May 2, 2017 from 2:00 to 2:30 p.m. PDT
PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Erin S. -Cox
Director of Investor Relations
Corporate Communications Contact:
Senior Vice President
Robert H. Uhl
Westwicke Partners, LLC
SOURCE PhaseRx, Inc.